<DOC>
	<DOCNO>NCT01660568</DOCNO>
	<brief_summary>We retrospectively review patient refractory relapsed ENKL receive gemcitabine-containing regimen</brief_summary>
	<brief_title>Gemcitabine NK/T Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>NK/T cell lymphoma relapse refractory disease gemcitabine contain treatment</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>